CHO based biosimilar cell lines

Bioceros has developed a portfolio of high producing cell lines expressing biosimilar proteins, such as fusion proteins, enzymes and monoclonal antibodies which are available for out-licensing.

These biosimilar cell lines are generated on our proprietary CHO-based platform, CHOBC© using (animal component free) of the shelf culture medium. The cell lines are GMP-ready, stable, high producing, fully documented and functionally characterized. All available QA approved documentation is accessible for our (potential) partners via a Virtual Data Room.

Biosimilar programs that are completed and ready for tech transfer to a CMO of choice by our partner, as well as programs in different development stages, can be found in the table below.

For more information please contact Oscar Hoogteijling at o.hoogteijling@bioceros.com or call +31 30 253 52 01

Biosimilar to

Designation

Antibody

Cell lines available

Yervoy© BC017 Ipilimumab Ongoing
Perjeta© BC019 Pertuzumab Ongoing
Entyvio© BC020 Vedolizumab Ongoing
Herceptin© BC002REEM Trastuzumab
Humira© BC004 Adalimumab
Erbitux© BC005 Cetuximab
Avastin© BC006 Bevacizumab
Rituxan/MabThera© BC007 Rituximab
Enbrel© BC008 Etanercept
Synagis© BC009 Palivizumab
Xolair© BC011NPI Omalizumab
Myozyme© BC012 Alglucosidase alfa